Venatorx Pharmaceuticals was awarded a Phase 2 SBIR Grant for novel approaches to address multi-drug resistant gram-negative infections. Venatorx may receive up to $3M of funding under the grant.
Venatorx Pharmaceuticals was awarded a Phase 2 SBIR Grant for novel approaches to address multi-drug resistant gram-negative infections. Venatorx may receive up to $3M of funding under the grant.
| You are using a browser that is not supported. Please consider changing your browser |